In an effort to increase ALS research, Biogen is contributing $5 million - and offering to match more - to entice researchers to conduct basic science and therapeutics research in the debilitating disease.
Cambridge startup Amylyx just raised $1.9 million in equity and grants for its combination drug that mediates stress in mitochondria and the endoplasmic reticulum.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Too much hype will make it hard to take the real credit later on.
For the 2.5 million people who donated after participating in the Ice Bucket Challenge, how is that money being spent?
Researchers are now linking some ALS incidence with folks who live near large bodies of water, a new piece in Scientific American points out. It writes: About five years ago, doctors at a New Hampshire hospital noticed a pattern in their ALS patients—many of them, like Gilmore, lived near water. Since then, researchers at Dartmouth-Hitchcock Medical Center […]
A lot of hopes were pinned on using dexpramipexole to treat those with ALS. But it the small molecule drug, thought to maintain mitochondrial function, flopped in Biogen Idec’s Phase 3 trials last year: Though fast-tracked in 2009 for the indication, it failed to show any statistical efficacy in improving the symptoms or lifespan of patients with Lou […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The ALS Ice Bucket Challenge recently took over social media and became a booming, chilling demonstration of the support for Lou Gehrig’s disease research. In this TED talk, Nancy Frates tells the story of how the family created the phenomenon after her son, 27-year-old Pete, was diagnosed with the disease. Pete’s diagnosis came about by […]
A cure for spinal cord injury? Diabetes? Macular degeneration? Hope or just hype? There are now some clinical trials using embryonic stem cells to treat serious diseases for which no other good therapy is currently available. But this is just the beginning of a major medical megatrend that will blossom forth in the coming years. […]